LIST OF FIGURES

Fig. No.	Figure Legends	Page No.
1.1	Synthesis of ACh and cholinergic neurotransmission.	4
1.2	Amyloidogenic (β-secretase) and non-amyloidogenic (α-secretase) pathways.	5
1.3	The process of tau aggregation, formation of NFTs, and neurodegeneration.	9
2.1	Schematic structural representation of (*R,S*)-1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine.	16
2.2	Structures of donepezil analogs with modification of benzyl and piperidine moieties.	17
2.3	Structures of minaprine and its most potent analog.	18
2.4	Structures of *N*-benzylpiperidine analogs tethered with variably substituted indole moieties.	19
2.5	The cyclopentathiophene substituted analogs of donepezil.	19
2.6	The *N*-benzylpiperidine and indolylpropargylamine tethered multitargeted hybrid.	20
2.7	Molecular hybrids of *N*-benzylpiperidine and 2-aminopyridine-3,5-dicarbonitrile.	20
2.8	The *N*-benzylpiperidine and indole molecular hybrid with multitargeted activities against AD.	21
2.9	Ferulic acid-based *N*-benzylpiperidine hybrids.	22
2.10	A molecular hybrid of *N*-benzylpiperidine and diarylthiazole as potential multitargeted ligand against AD.	23
2.11	A molecular hybrid of *N*-benzylpiperidine moiety of donepezil and coumarin.	23
2.12	Umbelic and caffeic acid-based molecular hybrids of *N*-benzylpiperidine.	24
2.13	Donepezil-like multitargeted compounds as AChE and BACE-1 inhibitors.	25
2.14	Donepezil-based hybrids of *N*-benzylpiperdine/benzylpiperazine moiety with benzimidazole or benzofuran.	25
2.15	Novel *N*-benzylpiperidine carboxamide derivatives.	26
2.16	1,3,4-Oxadiazole as GSK-3β and CDK-5 inhibitor.	26
2.17	1,3,4-Oxadiazoles as ChE and LOX inhibitors.	27
2.18	1,3,4-Oxadizole analogs with AChE inhibitory potential from the library of (*E*)-2-aryl-5-(3,4,5-trimethoxystyryl)-1,3,4-oxadiazoles and (*E*)-2-aryl-5-(2-benzo[d][1,3]diox-ol-5-yl)vinyl)-1,3,4-oxadiazoles.	27
2.19	Novel benzothiazole tethered 1,3,4-oxadiazole hybrids.	28
2.20	3-Piperidinyl-1,3,4-oxadiazole hybrid with AChE inhibitory activity.	28

Fig. No.	Figure Legends	Page No.
2.21	A multifunctional hybrid with 2-aminopyrimidine linked 1,3,4-oxadiazole to treat AD.	29
2.22	A molecular hybrid of 4-aminopyridine and 1,3,4-oxadiazole.	29
2.23	Molecular hybrids of 4-aminopyridine and 1,3,4-oxadiazole.	30
3.1	Design strategy for Part-I (Series I) ligands.	33
3.2	Design strategy for Part-II (Series II–V) ligands.	34
5.1	Favored binding sites in generated e-pharmacophore models. [A] AChE (PDB code: 4EY7) [B] BACE-1 (PDB code: 2ZJM).	58
5.2	3D Structures of cocrystallized ligands depicting numbering of favored residues. [A] AChE (PDB code: 4EY7) [B] BACE-1 (PDB code: 2ZJM).	59
5.3	Structures of common identified hits. [A] SEW06622 [B] AW01119 [C] PD00698.	60
5.4	Superimpose representation. [A] Donepezil redocked (green) and cocrystallized pose (blue) on AChE (RMSD: 0.4227 Å) [B] F1M redocked (green) and cocrystallized pose (blue) on BACE-1 (RMSD: 1.9161 Å).	62
5.5	Binding pattern of SEW06622 (**S_I3a**) depicted in orange colored ligand binding surface at the active pocket. [A] AChE (4EY7) [B] BACE-1 (2ZJM).	62
5.6	Binding pattern of **S_I3j** depicted in green colored ligand binding surface at the active pocket. [A] AChE (4EY7) [B] BACE-1 (2ZJM).	62
5.7	Binding pattern of **S_I4j** depicted in golden colored ligand binding surface at the active pocket. [A] AChE (4EY7) [B] BACE-1 (2ZJM).	62
5.8	Molecular dynamics studies of SEW06622 (**S_I3a)**-AChE (4EY7) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	64
5.9	Molecular dynamics studies of **S_I3j**-AChE (4EY7) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	64
5.10	Molecular dynamics studies of **S_I4j**-AChE (4EY7) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	65
5.11	Molecular dynamics studies of SEW06622 (**S_I3a**)–BACE-1 (2ZJM) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	65

Fig. No.	Figure Legends	Page No.
5.12	Molecular dynamics studies of **S_I3j**–BACE-1 (2ZJM) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	66
5.13	Molecular dynamics studies of **S_I4j**-BACE-1 (2ZJM) docked complex. [A] Histogram [B] Graphical representation showing percentage interactions with active site residues [C] Timeline representation showing interactions at each time frame.	66
5.14	Lineweaver-Burk plot for the kinetic study of hAChE inhibition by compound **S_I4j.**	82
5.15	Dixon plot of compound **S_I4j** at three different concentrations (0.03, 0.15, and 0.30 μM) showing Ki value of inhibitor as the negative intersection at the x-axis.	83
5.16	Effect of test compounds on Aβ aggregation inhibition. [A] Self-induced and [B] AChE-induced experiments.	87
5.17	Effect of test compounds on Aβ aggregation. [A] Self-induced and [B] AChE-induced Aβ aggregation.	87
5.18	AFM images of $A\beta_{1-42}$ aggregates (10 μM) incubated with or without inhibitor (**S_I4j)** at different time intervals (0, 3, 5, and 7 days).	88
5.19	Cell viability assay on neuroblastoma SH-SY5Y cell lines with increasing concentrations of **S_I4i** and **S_I4j**.	89
5.20	Effect of compounds **S_I4i**, **S_I4j**, and donepezil on scopolamine-induced cognition and memory improvement. [A] Spontaneous alternations (%) and [B] Total number of arm entries in the Y-maze experiment.	91
5.21	Results of *ex vivo* studies. [A] AChE activity- rate of substrate hydrolyzed [B] TBARS assay- levels of MDA [C] Superoxide dismutase assay- levels of SOD units.	92
5.22	Effect of compound **S_I4j** in spatial memory improvement on ICV $A\beta_{1-42}$-induced model [A] Escape latency time (ELT) [B] Number of platform crossings in target quadrant during the last 5 days of trials by Morris water maze experiment.	93
5.23	Lineweaver-Burk double reciprocal plot showing the mechanism of enzyme inhibition by compound **S_{III}10g** [A] hAChE inhibition with acetylthiocholine iodide (ATCI) as substrate [B] hBChE inhibition with butyrylthiocholine iodide (BTCI) as substrate.	120
5.24	The Dixon plots of compound **S_{III}10g** between Lineweaver-Burk double reciprocal slope and inhibitor concentrations. [A] Dissociation constant Ki = 0.026 μM for hAChE and [B] Dissociation constant Ki = 0.115 μM for hBChE.	120
5.25	Effect of test compounds on Aβ aggregation inhibition. [A] Self-induced and [B] AChE-induced experiments.	124
5.26	Effect of test compounds on Aβ aggregation. [A] Self-induced and [B] AChE-induced Aβ aggregation.	124

Fig. No.	Figure Legends	Page No.
5.27	AFM images of $A\beta_{1-42}$ aggregates (10 μM) incubated with or without inhibitor (**S_{III}10g)** at different time intervals (on days 0, 4, 7, and 10).	125
5.28	Cell viability assay on neuroblastoma SH-SY5Y cell lines with increasing concentrations of [A] **S_{III}10g** and [B] **S_{IV}14f.**	126
5.29	Effect of compounds **S_{III}10g**, **S_{IV}14f**, and donepezil on scopolamine-induced cognition and memory improvement. [A] Spontaneous alternations (%) and [B] Total number of arm entries in the Y-maze experiment.	128
5.30	Results of *ex vivo* studies. [A] AChE activity- rate of substrate hydrolyzed [B] TBARS assay- levels of MDA and [C] Superoxide dismutase assay- levels of SOD units.	129
5.31	Effect of compound **S_{III}10g** in spatial memory improvement on ICV $A\beta_{1-42}$-induced model [A] Escape latency time (ELT) [B] Number of platform crossings in target quadrant during the last 5 days of trials by Morris water maze experiment.	131
5.32	Effect of **S_{III}10g** on *in vivo* expression of Aβ and BACE-1 levels in the hippocampal region of the rat brain. [A] Representative bands in the Western blot analysis [B] Densitometric quantification showing attenuated levels of Aβ and [C] BACE-1, which were elevated with ICV administration of Aβ; [D] Immunostaining showing attenuated levels of Aβ and BACE-expression by **S_{III}10g** at 10× magnification after staining; [E & F] Quantification analysis of immunostains showing changes in burden (% area) of Aβ and BACE-1 levels, respectively.	132
5.33	Docking poses of ligands in the active site of AChE (4EY7). [A] **S_{III}10g** and [B] **S_{IV}14f.**	135
5.34	Docking poses of ligands in the active site of BACE-1 (2ZJM). [A] **S_{III}10g** and [B] **S_{IV}14f.**	135
5.35	Results of molecular dynamics simulation run of 100 ns for **S_{III}10g**-AChE (4EY7) docked complex. [A] Ligand-protein RMSD relative to protein backbone structure [B] Histogram showing interaction fractions and [C] Time-line graphical representation showing interaction with individual residues in each trajectory frame.	137
5.36	Results of molecular dynamics simulation run of 100 ns for **S_{IV}14f**-AChE (4EY7) docked complex. [A] Ligand-protein RMSD relative to protein backbone structure [B] Histogram showing interaction fractions and [C] Time-line graphical representation showing interaction with individual residues in each trajectory frame.	137
5.37	Results of molecular dynamics simulation run of 100 ns for **S_{III}10g**-BACE-1 (2ZJM) docked complex. [A] Ligand-protein RMSD relative to protein backbone structure [B] Histogram showing interaction fractions and [C] Time-line graphical representation showing interaction with individual residues in each trajectory frame.	138

Fig. No.	Figure Legends	Page No.
5.38	Results of molecular dynamics simulation run of 100 ns for **S_{IV}14f**-BACE-1 (2ZJM) docked complex. [A] Ligand-protein RMSD relative to protein backbone structure [B] Histogram showing interaction fractions and [C] Time-line graphical representation showing interaction with individual residues in each trajectory frame.	138
5.39	2D graphical representation of active site interactions in 100 ns molecular dynamics simulations runs. [A] **S_{III}10g**-AChE [B] **S_{IV}14f**-AChE [C] **S_{III}10g**-BACE-1 and [D] **S_{IV}14f**-BACE-1.	139

LIST OF SCHEMES

Scheme No.	Scheme Legends	Page No.
1	Synthesis of compounds from Series I (**S_I3a–o** and **S_I4a–o**).	39
2	Synthesis of compounds from Series II (**S_{II}9a–h**) and Series III (**S_{III}10a–h**).	40
3	Synthesis of compounds from Series IV (**S_{IV}14a–h**).	42
4	Synthesis of compounds from Series V (**S_V17a–h**).	44